Rufinamide oral suspension approved for seizures

Article

The FDA has approved rufinamide oral suspension 40 mg/mL as an adjunctive treatment for seizures associated with Lennox-Gastaut syndrome.

The FDA has approved rufinamide oral suspension 40 mg/mL as an adjunctive treatment for seizures associated with Lennox-Gastaut syndrome (LGS), a severe form of epilepsy.

Lennox-Gastaut syndrome usually begins before 4 years of age as a result of brain malformations, severe head injury, perinatal asphyxia, central nervous system infection, or inherited degenerative or metabolic disorders. Patients may experience frequent seizures. One-third of cases present with no perceivable causes.

Children with LGS display developmental delays and impaired intellectual function, information processing, and behavior.

Rufinamide is approved for children 4 years of age and older and adults. The new oral suspension benefits patients who prefer a liquid or who find tablets difficult to swallow.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Recent Videos
Ihuoma Eneli, MD; and Jamie Moore, MD, discuss pediatric obesity management
Remote monitoring expands possibilities for pediatric care, with Alisa Niksch, MD
John Loiselle, MD, talks recognizing pediatric musculoskeletal injuries
© 2025 MJH Life Sciences

All rights reserved.